Aug 5, 2025 8:00 am EDT Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Jul 23, 2025 8:00 am EDT Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Jul 3, 2025 4:30 pm EDT Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2025 6:55 am EDT Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Jun 23, 2025 8:00 am EDT Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Jun 2, 2025 8:00 am EDT Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
May 15, 2025 8:00 am EDT Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
May 12, 2025 8:00 am EDT Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
May 6, 2025 8:00 am EDT Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
May 5, 2025 8:00 am EDT Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision